Immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a meta-analysis

HIGHLIGHTS

• who: Alessandro Rizzo and colleagues from the , Bari, Italy Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna have published the paper: Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis, in the Journal: (JOURNAL) of 22/Nov/2022
• what: According to the results of the metaIn the analysis , the authors included four RCTs-IMbrave150, HIMALAYA, COSMIC-312, and analysis, treated with immune-based combinations reported longer median OSmetaand Figure 6.patients Forest plot of comparison between2176 immune-based combinations versus sorafenib monoORIENT-32-as a whole . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.